Deliargyris Efthymios 4
4 · Cytosorbents Corp · Filed Apr 2, 2024
Insider Transaction Report
Form 4
Deliargyris Efthymios
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2024-03-29+47,088→ 47,088 totalExercise: $0.95Exp: 2034-03-29→ Common Stock (47,088 underlying)
Footnotes (1)
- [F1]The reporting person participated in a voluntary salary reduction for the period from April 1, 2024, to December 31, 2024, and these stock options were granted in connection with the salary reduction. These stock options were issued pursuant to the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan. The shares underlying these stock options will vest fully on January 31, 2025, except as set forth on the corresponding non-qualified stock option agreement and subject to the reporting person's continued service as of the applicable vesting date.